Food Standards Australia New Zealand, (FSANZ) have approved Chr. Hansen’s 2’-FL human milk oligosaccharide for infant formula in Australian and New Zealand.
Said Jesper Sig Mathiasen, senior vice president, Chr. Hansen HMO: “As one of the leading suppliers of HMOs, we are pleased to have our 2’-FL HMO ingredient officially approved by national authorities in Australia and New Zealand. In these attractive markets we can now support our customers in supplying leading infant formula products that are closer to breast milk.”
HMO 2’-FL is not only the most studied HMO; it is also the most abundant, making up 20-30% of the total HMO composition in breast milk. Discovered in 1954 it was the first HMO to be commercially produced and recognised as safe by the North American (FDA) and European (EFSA) food safety authorities and are approved as an ingredient for infant formula in many global markets, now including Chr. Hansen’ 2’-FL for Australia and New Zealand.
Added Dr. Katja Parschat, head of Research & Development, Chr. Hansen HMO: “Breastfeeding is the best way to ensure infant health and recommended by WHO. At Chr. Hansen, we further aim to support the healthy development of infants that cannot be breastfed by providing HMOs as an ingredient for infant formula.
“The latest research shows that HMOs contribute to health benefits, such as supporting the immune system and healthy brain development. Also, HMOs are indicated to support gut maturation and resilience, as well as promotion of a balanced gut microbiome. We are happy to be able to offer our solutions to customers in Australia and New Zealand now.” For more visit chr-hansen.com